Induction of balance and breadth in the immune response is beneficial for the control of SIVmac239 replication in rhesus monkeys

Journal of Infection

Volumn 60, Issue 5, 2010, Pages 371-381

  Sun, Caijun ^a,b   Zhang, Lei ^a   Zhang, Maochao ^a   Liu, Yichu ^a   Zhong, Miao ^a,b   Ma, Xin ^a   Chen, Ling ^a,c  

^a GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

HIV vaccine; Immune balance; Immune breadth; Protection; SIVmac239

Indexed keywords

ADENOVIRUS VECTOR; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEF PROTEIN; POL PROTEIN; REV PROTEIN; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIF PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; VPR PROTEIN; VPX PROTEIN;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREGULATION; INFECTION PREVENTION; LYMPHOCYTE PROLIFERATION; MACACA; MALE; MOUSE; NONHUMAN; PROCESS OPTIMIZATION; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VIRUS REPLICATION;

ANIMALS; MACACA MULATTA; MICE; MICE, INBRED C57BL; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

EID: 77952548859     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2010.03.005     Document Type: Article

References (46)

1. Moog C. Immune responses that correlate with HIV-1 protection?. AIDS 2008, 22(12):1461-1462.
2. Maness N.J., Yant L.J., Chung C., Loffredo J.T., Friedrich T.C., Piaskowski S.M., et al. Comprehensive immunological evaluation reveals surprisingly few differences between elite controller and progressor Mamu-B*17-positive Simian immunodeficiency virus-infected rhesus macaques. J Virol 2008, 82(11):5245-5254.
3. Letvin N.L., Rao S.S., Dang V., Buzby A.P., Korioth-Schmitz B., Dombagoda D., et al. No evidence for consistent virus-specific immunity in simian immunodeficiency virus-exposed, uninfected rhesus monkeys. J Virol 2007, 81(22):12368-12374.
4. Heeney J.L., Plotkin S.A. Immunological correlates of protection from HIV infection and disease. Nat Immunol 2006, 7(12):1281-1284.
5. Cohen J. AIDS vaccine trial produces disappointment and confusion. Science 2003, 299:1290-1291.
6. Cohen J. Promising AIDS vaccine's failure leaves field reeling. Science 2007, 318:28-29.
7. Barouch D.H. Challenges in the development of an HIV-1 vaccine. Nature 2008, 455:613-619.
8. Benlahrech A., Harris J., Meiser A., Papagatsias T., Hornig J., Hayes P., et al. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci USA 2009, 106(47):19940-19945.
9. Hutnick N.A., Carnathan D.G., Dubey S.A., Cox K.S., Kierstead L., Ratcliffe S.J., et al. Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+T cells. Nat Med 2009, 15(8):876-878.
10. O'Brien K.L., Liu J., King S.L., Sun Y.H., Schmitz J.E., Lifton M.A., et al. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med 2009, 15(8):873-875.
11. Perreau M., Pantaleo G., Kremer E.J. Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J Exp Med 2008, 205(12):2717-2725.
12. Steinbrook R. One step forward, two steps back - will there ever be an AIDS vaccine?. N Engl J Med 2007, 357(26):2653-2655.
13. Watkins D.I., Burton D.R., Kallas E.G., Moore J.P., Koff W.C. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 2008, 14(6):617-621.
14. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002, 415(6869):331-335.
15. Schell J., Rose N.F., Fazo N., Marx P.A., Hunter M., Ramsburg E., et al. Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge. Vaccine 2009, 27(7):979-986.
16. Sealy R., Zhan X., Lockey T.D., Martin L., Blanchard J., Traina-Dorge V., et al. SHIV infection protects against heterologous pathogenic SHIV challenge in macaques: a gold-standard for HIV-1 vaccine development?. Curr HIV Res. 2009, 7(5):497-503.
17. Ambrose Z., KewalRamani V.N., Bieniasz P.D., Hatziioannou T. HIV/AIDS: in search of an animal model. Trends Biotechnol 2007, 25(8):333-337.
18. Morgan C., Marthas M., Miller C., Duerr A., Cheng-Mayer C., Desrosiers R., et al. The use of nonhuman primate models in HIV vaccine development. PLoS Med 2008, 5(8):e173.
19. Casimiro D.R., Wang F., Schleif W.A., Liang X., Zhang Z.Q., Tobery T.W., et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J Virol 2005, 79(24):15547-15555.
20. Engram J.C., Dunham R.M., Makedonas G., Vanderford T.H., Sumpter B., Klatt N.R., et al. Vaccine-induced, Simian immunodeficiency virus-specific CD8+T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression. J Immunol 2009, 183(1):706-717.
21. Vogel T.U., Reynolds M.R., Fuller D.H., Vielhuber K., Shipley T., Fuller J.T., et al. Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. J Virol 2003, 77(24):13348-13360.
22. Pal R., Venzon D., Letvin N.L., Santra S., Montefiori D.C., Miller N.R., et al. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol 2002, 76(1):292-302.
23. Patterson L.J., Malkevitch N., Venzon D., Pinczewski J., Gómez-Román V.R., Wang L., et al. Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol 2004, 78(5):2112-2121.
24. Suh Y.S., Park K.S., Sauermann U., Kim K.S., Ahn S.S., Franz M., et al. Prolonged survival of vaccinated macaques after oral SIVmac239 challenge regardless of viremia control in the chronic phase. Vaccine 2008, 26(51):6690-6698.
25. Casimiro D.R., Cox K., Tang A., Sykes K.J., Feng M., Wang F., et al. Efficacy of multi-valent adenovirus-based vaccine against simian immunodeficiency virus challenge. J Virol 2009 Dec 30, [Epub ahead of print].
26. Kiepiela P., Ngumbela K., Thobakgale C., Ramduth D., Honeyborne I., Moodley E., et al. CD8+T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007, 13:46-53.
27. Casimiro D.R., Tang A., Chen L., Fu T.M., Evans R.K., Davies M.E., et al. Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003, 77:7663-7668.
28. Gorelick R.J., Benveniste R.E., Lifson J.D., Yovandich J.L., Morton W.R., Kuller L., et al. Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost. J Virol 2000, 74:11935-11949.
29. Lun W.H., Takeda A., Nakamura H., Kano M., Mori K., Sata T., et al. Loss of virus-specific CD4(+) T cells with increases in viral loads in the chronic phase after vaccine-based partial control of primary simian immunodeficiency virus replication in macaques. J Gen Virol 2004, 85(Pt 7):1955-1963.
30. Daniel M.D., Kirchhoff F., Czajak S.C., Sehgal P.K., Desrosiers R.C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992, 258(5090):1938-1941.
31. Horton H., Vogel T.U., Carter D.K., Vielhuber K., Fuller D.H., Shipley T., et al. Cellular immunity for prevention and clearance of HIV infection. Curr Mol Med 2003, 3:195-208.
32. Mansfield K., Lang S.M., Gauduin M.C., Sanford H.B., Lifson J.D., Johnson R.P., et al. Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery. J Virol 2009, 82(8):4135-4148.
33. Kong W.P., Wu L., Wallstrom T.C., Fischer W., Yang Z.Y., Ko S.Y., et al. Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J Virol 2009, 83:2201-2215.
34. Johansson B.E., Moran T.M., Kilbourne E.D. Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins. Proc Natl Acad Sci USA 1987, 84:6869-6873.
35. Grifantini R., Finco O., Bartolini E., Draghi M., Del Giudice G., Kocken C., et al. Multi-plasmid DNA vaccination avoids antigenic competition and enhances immunogenicity of a poorly immunogenic plasmid. Eur J Immunol 1998, 28:1225-1232.
36. Maggiorella M.T., Sernicola L., Crostarosa F., Belli R., Pavone-Cossut M.R., Macchia I., et al. Multiprotein genetic vaccine in the SIV-Macaca animal model: a promising approach to generate sterilizing immunity to HIV infection. J Med Primatol 2007, 36:180-194.
37. Zhang Z.Q., Fu T.M., Casimiro D.R., Davies M.E., Liang X., Schleif W.A., et al. Mamu-A*01 allele-mediated attenuation of disease progression in simian-human immunodeficiency virus infection. J Virol 2002, 76(24):12845-12854.
38. Ma X., Tang L.H., Qu L.B., Ma J., Chen L. Identification of 17 novel major histocompatibility complex-A alleles in a population of Chinese-origin rhesus macaques. Tissue Antigens 2009, 73(2):184-187.
39. Vogel T., Norley S., Beer B., Kurth R. Rapid screening for Mamu-A1-positive rhesus macaques using a SIVmac Gag peptide-specific cytotoxic T-lymphocyte assay. Immunology 1995, 84(3):482-487.
40. Staprans S.I., Barry A.P., Silvestri G., Safrit J.T., Kozyr N., Sumpter B., et al. Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci USA 2004, 101(35):13026-13031.
41. Barouch D.H., Liu J., Lynch D.M., O'Brien K.L., La Porte A., Simmons N.L., et al. Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against SIV challenge in rhesus monkeys. J Virol 2009, 83(18):9584-9590.
42. Douek D.C., Brenchley J.M., Betts M.R., Ambrozak D.R., Hill B.J., Okamoto Y., et al. HIV preferentially infects HIV-specific CD4 + T cells. Nature 2002, 417(6884):95-98.
43. Grundner C., Pancera M., Kang J.M., Koch M., Sodroski J., Wyatt R. Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins. Virology 2004, 330(1):233-248.
44. Gruber A., Chalmers A.S., Rasmussen R.A., Ong H., Popov S., Andersen J., et al. Dendritic cell-based vaccine strategy against human immunodeficiency virus clade C: skewing the immune response toward a helper T cell type 2 profile. Viral Immunol 2007, 20(1):160-169.
45. Wasik T.J., Jagodzinski P.P., Hyjek E.M., Wustner J., Trinchieri G., Lischner H.W., et al. Diminished HIV-specific CTL activity is associated with lower type 1 and enhanced type 2 responses to HIV-specific peptides during perinatal HIV infection. J Immunol 1997, 158(12):6029-6036.
46. Spellberg B., Edwards J.E. Type 1/type 2 immunity in infectious diseases. Clin Infect Dis 2001, 32:76-102.